Corium International (CORI) Stock Rating Lowered by Zacks Investment Research

Corium International (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “

Several other research analysts have also commented on the company. HC Wainwright set a $14.00 price target on Corium International and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub lowered Corium International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. ValuEngine upgraded Corium International from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $14.00 target price on shares of Corium International in a research report on Tuesday, March 27th. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $13.00.

Corium International traded down $0.30, hitting $9.17, on Thursday, according to MarketBeat. The company had a trading volume of 259,400 shares, compared to its average volume of 274,425. The firm has a market cap of $352.21 million, a P/E ratio of -5.59 and a beta of 1.61. Corium International has a 12-month low of $9.42 and a 12-month high of $9.75. The company has a current ratio of 1.40, a quick ratio of 1.34 and a debt-to-equity ratio of 5.91.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). The company had revenue of $10.06 million during the quarter, compared to analysts’ expectations of $7.07 million. Corium International had a negative return on equity of 359.26% and a negative net margin of 156.05%. research analysts forecast that Corium International will post -1.47 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. boosted its position in shares of Corium International by 377.8% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 86,000 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 68,000 shares during the period. Tamarack Advisers LP boosted its position in shares of Corium International by 6.3% during the fourth quarter. Tamarack Advisers LP now owns 1,010,000 shares of the biopharmaceutical company’s stock valued at $9,706,000 after buying an additional 60,000 shares during the period. California Public Employees Retirement System purchased a new position in shares of Corium International during the fourth quarter valued at approximately $310,000. Schwab Charles Investment Management Inc. boosted its position in shares of Corium International by 47.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after buying an additional 15,909 shares during the period. Finally, RTW Investments LP boosted its position in shares of Corium International by 1.4% during the fourth quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock valued at $16,334,000 after buying an additional 24,174 shares during the period. Institutional investors and hedge funds own 90.68% of the company’s stock.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply